Sponsors / ABVX
ABVX

Abivax S.A.

Company identity checked against sources

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
12Trials in this database
11Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor TreatmentNCT02735863ABVXPhase 2Completed2017-08-30Actual
ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisNCT03093259ABVXPhase 2Completed2018-07-25Actual
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative ColitisNCT03368118ABVXPhase 2Completed2022-07-12Actual
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative ColitisNCT03760003ABVXPhase 2Completed2021-04-01Actual
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative ColitisNCT04023396ABVXPhase 2Completed2023-02-23Actual
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid ArthritisNCT04049448ABVXPhase 2Completed2023-01-23Actual
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19NCT04393038ABVXPhase 2, Phase 3Terminated2021-03-05Actual
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisNCT05177835ABVXPhase 2Active not recruiting2028-03Estimated
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1NCT05507203ABVXPhase 3Completed2025-06-24Actual
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2NCT05507216ABVXPhase 3Completed2025-06-24Actual
ABTECT - MaintenanceNCT05535946ABVXPhase 3Active not recruiting2026-04-28Actual
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's DiseaseNCT06456593ABVXPhase 2Recruiting2026-12Estimated

Latest recorded trial changes

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

NCT05507203 · Abivax S.A.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8

+ Updated value

measure: Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

NCT05507216 · Abivax S.A.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8

+ Updated value

measure: Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19

NCT04393038 · Abivax S.A.

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive

+ Updated value

measure: Rate of Responders: i.e. Rate of Patients Who do Not Require Use of High-flow Oxygen Invasive or Non-invasive Mechanical Ventilation (IMV and NIV, Respectively) Within 28 Days and Who Are Alive at the End of the 28 Days Period.

Check registry source · The saved outcome text may be shortened. Check the source for full wording.
ABTECT - Maintenance

NCT05535946 · Abivax S.A.

Enrollment · participant countRecorded edit
− Previous value

count: 1050; type: ESTIMATED

+ Updated value

count: 1116; type: ACTUAL

Check registry source